posted on 2016-04-20, 00:00authored byBin Zhao, Yixuan Li, Pan Xu, Yang Dai, Cheng Luo, Yiming Sun, Jing Ai, Meiyu Geng, Wenhu Duan
Fibroblast growth factor receptors
(FGFRs) are important targets
for cancer therapy. Herein, we describe the design, synthesis, and
biological evaluation of a novel series of 1H-pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase
inhibitors. On the basis of its excellent in vitro potency and favorable pharmacokinetic properties, compound 7n was selected for in vivo evaluation and
showed significant antitumor activity in a FGFR1-driven H1581 xenograft
model. These results indicated that 7n would be a promising
candidate for further drug development.